

Special Issue

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Cancer Therapy

Message from the Guest Editors

Cancer with peritoneal metastasis is a special form of metastasis and is difficult to treat, though many new drugs have been applied. For the past few decades, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have provided another treatment option. Many patients do not experience recurrence after CRS/HIPEC. However, it seems that CRS/HIPEC is only effective for some types of cancer and there exist conflicts regarding treatment results. Furthermore, there is still no global consensus regarding timing, temperature setting, hyperthermic duration or even drug choice. Genetic alteration may be a factor affecting the treatment results. Minimal invasive CRS/HIPEC is currently in development. Many trials are ongoing, with possible new findings on the horizon. This Special Issue welcomes reviews, original research articles of clinical works, new techniques, diagnostic tools, clinical trials and experimental studies. Dr. Mao-Chih Hsieh

Guest Editors

Dr. Mao-Chih Hsieh

1. Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

Dr. Hsin-Hsien Yu

1. Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan

Deadline for manuscript submissions

closed (15 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/179521

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)